CTLA4 and neoplasm: IPS-PD-1/PD-L1/PD-L2_pos and IPS-CTLA-4_pos was higher in low-risk group patients than in high-risk group patients (Figures 10E,F), indicating that low-NRG_risk gastric cancer patients might have higher tumor immunogenicity and benefit from anti- PD-1/PD-L1/PD-L2 and anti- CTLA-4 blocker immunotherapy.